Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation  by Ho, Vincent T. et al.
From the
Biolo
Schoo
Financial d
*V.T.H. a
consid
Correspon
Farbe
MA 0
Received N
 2011 Am
1083-8791
doi:10.101
1196Use of Matched Unrelated Donors Compared with
Matched Related Donors Is Associated with Lower
Relapse and Superior Progression-Free Survival after
Reduced-Intensity Conditioning Hematopoietic Stem
Cell Transplantation
Vincent T. Ho,1,* Haesook T. Kim,2,* Julie Aldridge,2 Deborah Liney,1 Grace Kao,1
Philippe Armand,1 John Koreth,1 Corey Cutler,1 Jerome Ritz,1
Joseph H. Antin,1 Robert J. Soiffer,1 Edwin P. Alyea11Cen
gy, D
l, Bo
isclosu
nd H
ered
ding
r Ca
2115
ove
eric
/$36
6/j.bAs success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies
primarily on graft-versus-leukemia (GVL) activity, increased minor HLA disparity in unrelated compared
to related donors could have a significant impact on transplant outcomes. To assess whether use of unrelated
donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (MRD), we
retrospectively studied 433 consecutive T-replete 6/6 HLAmatched URD (n5 246) and MRD (n5 187) RIC
HSCT for hematologic malignancies at our institution. Diseases included: acute myelogenous leukemia
(AML) (127), non-Hodgkin lymphoma (NHL) (71), chronic lymphocytic leukemia (CLL) (68), myelodysplastic
syndrome (MDS) (64), Hodgkin disease (HD) (40), chronic myeloid leukemia (CML) (25), multiple myeloma
(MM) (23), myeloproliferative disorder (MPD) (12), acute lymphoblastic leukemia (ALL) (7), and other leu-
kemia (1). All received uniform fludarabine and intravenous busulfan conditioning, and GVHD prophylaxis
with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/sirolimus 6 mini-MTX. Unrelated donors
were younger compared to MRD (median donor age: 33 years versus 52 years, P\ .0001), and provided
larger CD341 products (median CD341 cells infused: 8.7  106/kg versus 7.5  106/kg, P5 .002). Distribu-
tion of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts.
Cumulative incidence of grade II-IV acute GVHD (at day 1180), 2-year chronic GVHD, and 2-year nonre-
lapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and MRD, respec-
tively (P 5 NS). Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P 5 .005).
With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly bet-
ter in unrelated donor transplants, 39.5% for URD, and 29% for MRD (P 5 .01). Overall survival (OS) at
2 years were 56% for URD versus 50% for MRD (P 5 .53). In multivariable analysis, URD was associated
with a lower risk of relapse (hazard ratio [HR] 0.67, P 5 .002) and superior PFS (HR 0.69, P 5 .002). These
results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing
impact on future donor selection in RIC HSCT.
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Reduced-intensity conditioning (RIC) regimens are
increasingly used to facilitate hematopoietic stem cell
transplantation (HSCT) in patients with advanced age
or medical comorbidity, primarily because RIC HSCT
is well tolerated and associated with less toxicity [1-3].
Unlike myeloablative HSCT where dose intensity
intrinsically reduces tumor burden, RIC HSCT
depends largely on the graft-versus-leukemia (GVL)
effect. As such, the extent ofminorHLAdisparity in un-
related compared to related donors could have a signifi-
cant impact on transplant outcomes.
Biol Blood Marrow Transplant 17:1196-1204, 2011 1197URD vs. MRD in RIC HSCTA number of studies in the myeloablative setting
have shown that matched related donors (MRD) are
superior to unrelated donors (URD), mainly because
the latter are associated with greater graft-versus-
host disease (GVHD) and transplant-related mortality
(TRM) [4-8]. With more refined HLA typing and
improved supportive care, TRM after allogeneic
HSCT has declined over the past 2 decades [9], and
differences in outcomes between URD and MRD
HSCT have become less apparent [10-14].
The relative benefits and risks of MRD versus
URD in RIC HSCT remain to be elucidated. In RIC
HSCT, early TRM is reduced, and the importance
of GVL in preventing relapse is magnified. Recent re-
ports have shown that URD RIC HSCT can be asso-
ciated with equivalent [15-17], or possibly, superior
disease control after RIC HSCT for conditions such
as advanced acute myelogneous leukemia (AML),
chronic lymphocytic leukemia (CLL), and mantle
cell lymphoma [12,18,19]. Moreover, there may be
an advantage in the ability to use younger donors and
to avoid female donors in male recipients.
To further address this question, we performed
a retrospective cohort analysis comparing patients
who underwent RIC HSCT from MRD and URD at
our institution.PATIENTS AND METHODS
Patients
All patients undergoing RIC HSCT with fludara-
bine/busulfan conditioning from HLA matched
URD or MRD at the Dana-Farber/Brigham and
Women’s Cancer Center between August 2002 and
December 2008, and who received tacrolimus-based
GVHD prophylaxis without T cell depletion were in-
cluded. All donor-recipient pairs were at minimum
HLA allele matched at A, B, and DRB1 (6/6 match).
High-risk disease was defined as acute leukemia or
CML beyond first complete remission/first chronic
phase (CR1/CP1), myelodysplastic syndrome (MDS)
other than de novo refractory anemia/ringed sidero-
blasts (RA/RARS), and CLL/lymphoma/myeloma
without complete remission/partial remission (CR/
PR) at the time of transplant. All patients provided
consent for use of protected health data for research
as approved by the institutional review board of the
Dana-Farber/Harvard Cancer Center.Conditioning Regimen and Supportive Care
All patients received fludarabine (30 mg/m2/day
i.v. 4) and intravenous busulfan (0.8 mg/kg every
12 hours or every 24 hours  4 days). The twice-daily
dosing busulfan (BU) regimen was restricted to a
few protocols in patients with advanced CLL andMDS/AML. A majority (97%) received granulocyte
colony-stimulating factor (G-CSF) mobilized periph-
eral blood stem cells (PBSCs). During the first year, all
patients received acyclovir as herpes simplex virus/
vericeller zoster virus (HSV/VZV) prophylaxis, and
sulfamethoxazole/trimethoprim or atovaquone as pro-
phylaxis against Pneumocystis jirovecii. Patients were
monitored for cytomegalovirus (CMV) reactivation
during the first 100 days after transplantation, and
pre-emptive therapy with valganciclovir was given if
CMV reactivation occurred.
GVHD Prophylaxis
GVHDprophylaxis consistedof either tacrolimus1
mini-methotrexate (days11, 3, 6, and 11), or tacrolimus
and sirolimus 6 mini-methotrexate (days 11, 3, and 6)
as previously described [20,21]. Taper of immune
suppression was initiated 2 to 4 months posttransplant,
with the goal to be off by approximately 6 months in
the absence of GVHD. No pre-emptive or planned
prophylactic donor lymphocyte infusions were given.
Acute GVHD (aGVHD) was graded by the consensus
grading criteria [22].
Chimerism Analysis
Total donor chimerism was assessed from unfrac-
tionated bone marrow aspirates and/or blood at ap-
proximately days 130 and 1100. Genotyping was
determined by short tandem repeat typing using the
ABI Profiler Plus Kit (Applied Biosystems Inc., Bed-
ford, MA) and an ABI 310 Genetic Analyzer. ‘‘Infor-
mative’’ alleles specific to donor or recipient were
used for chimerism determination.
Statistical Methods
Descriptive statistics was used to summarize pa-
tient characteristics. The Wilcoxon rank sum test,
chi-square test, or Fisher’s exact test was used for 2
sample comparisons. All tests were 2 sided. Cumula-
tive incidence curves for relapse and nonrelapse mor-
tality (NRM) were constructed reflecting time to
relapse and time to nonrelapse death as competing
risks. The difference between cumulative incidence
curves in the presence of a competing risk was tested
using the Gray method [23]. For patients who received
.1 RIC HSCT, only the first transplant was consid-
ered in the analysis, except in the analysis of overall
survival (OS), which was measured from the time of
transplantation to death from any cause. OS and
progression-free survival (PFS) were calculated using
the Kaplan-Meier method. The log-rank test was
used for comparisons of Kaplan-Meier curves. Prog-
nostic factors for OS and PFS were examined in Cox
proportional hazard models. Prognostic factors for
relapse and nonrelapse death were examined in com-
peting risks regression model [24]. Proportional
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to modeling, a variable clustering analysis on all cova-
riates was performed using a hierarchical clustering
with Hoeffding’s D statistic and squared Pearson cor-
relation in R (v2.10.1) and VARCLUS in SAS 9.2 (SAS
Institutute Inc., Cary, NC) to assess collinearity and/
or redundancy of covariates. Of covariates, donor age
and donor type were found to be highly correlated.
Thus, donor age was not included in the final model
for all patients. Instead, donor age was examined sep-
arately in each donor type (URD, MRD).RESULTS
Patient Characteristics
Characteristics of the 433 patients are shown in
Table 1. The median patient ages were 57 (range:
18-73) and 56 years (range: 19-71) for the URD and
MRD groups, respectively. The 2 cohorts were bal-
anced in gender, disease, disease risk, prior transplan-
tation, CMV serology status, and stem cell source. The
distribution of MRD and URD RIC stem cell trans-
plant (SCT) performed each year from 2002 through
2008 were also well balanced. As expected, donors
for MRD were significantly older: median related do-
nor age was 52 years (range: 12-73), compared to 33
years (range: 18-60) for URD, P \ .0001. Median
number of CD341 stem cells infused was higher in
the URD cohort, 8.8  106 CD341 cells/kg (range:
0.26-48) versus 7.6  106 CD341 cells/kg (range:
0.69-38), P 5 .002. There were more female donor/
male recipient gender mismatches in the MRD cohort
(33% versus 22%, P 5 .002). Among URD, 26 (11%)
had a single mismatch at HLA-C, compared to 2 (1%)
in the MRD cohort, P\ .0001.
The preparative regimen was fludarabine and sin-
gle daily dosing intravenous busulfan in 81% of the
URD and 86% of the MRD patients (P5 .20). Distri-
bution of GVHD prophylaxis regimens and year of
transplantation were similar. Median follow-up time
among survivors was 26.5 months (range: 6.0-80.4
months) for URD and 35.8 months (range: 6.7-74.3
months) for MRD (P 5 .25).
Engraftment
Approximately half of the patients (47% URD ver-
sus 49% MRD) never developed absolute neutropenia,
and 44% and 48%, respectively, did not have platelets
less than\20,000 cells/mL. Among patients whose neu-
trophil or platelet counts nadired,median neutrophil re-
covery time was 13 days for both cohorts (P5 .20), and
time to platelet recovery was 20 days for URD, 21 days
forMRD (P5 .79). Donor chimerism results in the first
4 months after transplantation were also similar. At ap-
proximately day 130, 67% and 61% of URD and
MRD recipients, respectively, achieved $90% donorchimerism (P5 .24). At approximately day1100, 65%
of the URD recipients retained .90% donor chime-
rism, compared to57%in theMRD(P5 .17). Incidence
of graft failure, defined as complete loss of donor chime-
rism in the absenceof disease relapse, or decline in donor
chimerism\50% in the absence of disease relapse that
necessitated donor lymphocyte infusion or second
HSCT, were 1.6% and 2.1% for URD and MRD, re-
spectively (P5 .73).Twopatientsdevelopedaposttrans-
plant B cell lymphoproliferative disorder at 3 and 6
months after RICHCT; bothwereURDand both cases
were EBV negative by pathologic stains.
GVHD
As shown on Figure 1A, the cumulative incidence
of grade II-IV aGVHD (at day1180) was 20% in
URD, versus 14% inMRD (P5 .18). The 180-day in-
cidence of grade III-IV aGVHDwas 8% for URD and
5% and MRD (P 5 .27). The cumulative incidence of
chronic GVHD (cGVHD) at 2 years was 55% among
URD, and 51% among MRD (P 5 .13), Figure 1B.
The 2-year cumulative incidence of extensive cGVHD
was 45% in URD and 36% in MRD (P 5 .03).
Disease Relapse and NRM
As shown on Table 2a and Figure 2, the 2-year cu-
mulative incidence of relapse was 52% for URD versus
65% forMRD (P5 .005). In amultivariable competing
risks regression model, the hazard ratio (HR) for re-
lapse remained much lower in patients with unrelated
donors (HR 0.67; 95% confidence interval [CI] 0.52-
0.86; P 5 .002) (Table 2b). High-risk disease (HR
1.69, 95% CI 1.28-2.22; P 5 .0002), myeloid disease
(HR 1.41, 95% CI 1.06-1.86; P 5 .02) were indepen-
dently associated with increased relapse risk. Higher
busulfan dose was associated with a lower relapse risk
(HR 0.65, 95% CI 0.44-0.97; P5 .03) (Figure 4C).
Cumulative incidence of NRM at 2 years was 8%
for URD versus 6% for MRD recipients (P 5 .33).
There was a significant improvement in NRM for
both cohorts correlated with year of transplantation.
Two-year NRM incidence for URD and MRD trans-
plants performed prior to 2004 were 16% and 14%,
respectively, compared to 6% and 3% after 2004
(P 5 .17 for URD; P 5 .03 for MRD).
In multivariable analysis, URD versus MRD was
not associated with a risk of NRM (HR 1.29; 95% CI
0.65-2.57;P5 .47). Year of transplantation (\2004 ver-
sus$2004) was the only significant factor for the risk of
NRM (HR 0.31, 95% CI 0.15-0.63, P 5 .001)
(Figure 4D).
PFS and OS
Withmedian follow-up of over 2 years for survivors
in both cohorts, the 2-year PFS was 39.5% (95% CI,
33%-46%) for URD, and 29% (95% CI, 22%-36%)
Table 1. Patient Characteristics
URD MRD
P Valuen 5 246 % n 5 187 %
Patient age .91
$50 181 74 136 73
<50 65 26 51 27
median (range) 57 (18, 73) 56 (19, 71) .12
Donor age, median (range) 33 (18, 60) 52 (12, 73) <.0001
Sex .42
M 161 65 115 62
F 85 35 72 39
Donor-recipient gender .002
Female/male 53 22 62 33
MM 108 44 53 28
FF 37 15 39 21
MF 48 20 33 18
Prior myeloablative transplant 79 32 63 34 .76
Autologous 73 30 50 27
Allogeneic 5 2 12 6
Syngeneic 1 <1.0 1 <1.0
Diagnosis —
ALL 6 2 1 <1.0
AML 68 28 59 32
CLL, SLL, PLL 42 17 26 14
CML 12 5 8 4
Hodgkin disease 27 11 13 7
MDS 39 16 25 13
Multiple myeloma 6 2 17 9
MPD 7 3 5 3
NHL 39 16 32 17
Mast cell leukemia — — 1 < 1.0
Risk status .12
High risk* 144 59 95 51
Low risk 102 41 92 49
Stem cell source —
Bone marrow 11 4 1 <1.0
PBSC 235 96 185 99
BM and PBSC — — 1 < 1.0
Conditioning regimen .2
Flu-BU1 (total 3.2 mg/kg BU) 200 81 161 86
Flu-BU2 (total 6.4 mg/kg BU) 46 19 26 14
GVHD prophylaxis .91
Tacrolimus/sirolimus ± mMTX 192 78 145 78
Tacrolimus/mMTX 54 22 42 22
HLA matching <.0001
8/8 HLA match 220 89 185 99
Single C mismatch (7/8 match) 26 11 2 1
D/R CMV serology status .86
Negative/negative 79 32 64 34
Any positive 165 67 121 65
Missing 2 0.8 2 1.1
Year of transplant .17
2002 14 6 11 6
2003 37 15 32 17
2004 39 16 34 18
2005 35 14 26 14
2006 31 13 37 20
2007 42 17 25 13
2008 48 20 22 12
Median CD34+ cells (106/kg) infused 8.68 7.46 .002
Median follow-up for survivors (months) 26.5 (6-80) 35.8 (6.7-74) .25
CLL indicates chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; MPD, myeloproliferative disorder; ALL,
acute lymphoblastic leukemia; MM, multiple myeloma; URD, unrelated donor; MRD, matched related donor; CMV, cytomegalovirus; AML, acute mye-
logenous leukemia; GVHD, graft-versus-host disease; NHL, non-Hodgkin leukemia; PBSC, peripheral blood stem cells; BM, bone marrow; FLU, fludar-
abine; BU, busulfan; SLL, small lymphocytic leukemia; mMTX, mini-methotrexate; PLL, prolymphocytic leukemia.
High risk defined as: acute leukemia or CML beyond CR1/CP1, MDS other than de novo RA/RARS, or CLL, lymphoma, myeloma not in CR/PR at the
time of transplant.
Biol Blood Marrow Transplant 17:1196-1204, 2011 1199URD vs. MRD in RIC HSCTforMRD,P5 .01 (Table 2a andFigure 3A).The 2-year
estimate of OS was 56% for URD versus 50% for
MRD, P 5 .53. (Table 2a and Figure 3B).In a multivariable Cox regression model for PFS
(Table 2b and Figure 4B), URD was associated with
superior PFS compared with MRD (HR 0.69; 95%
Figure 1. Cumulative incidence of GVHD, with death as a competing
risk. (A) Grade II-IV acute GVHD; (B) chronic GVHD.
Figure 2. Cumulative incidence of relapse and NRM as competing
risks.
1200 Biol Blood Marrow Transplant 17:1196-1204, 2011V. T. Ho et al.CI 0.54-0.88; P 5 .002). High-risk disease (HR 1.72,
95% CI 1.33-2.23; P \ .0001), and myeloid malig-
nancy (HR 1.45, 95% CI 1.11-1.89; P 5 .007) were
associated with worse PFS. Prior HSCT was border-
line significantly associated with lower PFS (HR
1.30, 95%CI 0.98-1.71; P5 .065). Recipient age, F/M
gender mismatch, sirolimus GVHD prophylaxis,Table 2a. Results of Univariable Analysis for URD versus
MRD
URD MRD
P Value2-year estimate (95% CI) 2-year estimate (95% CI)
Relapse* 52% (46%-59%) 65% (58%-72%) .005
NRM* 8.4% (4.6%-12.2%) 5.7% (7.2%-9.2%) .33
PFS 39.5% (33%-46%) 29% (22%-36%) .01
OS 56% (48%-62%) 50% (42%-57%) .53
OS indicates overall survival; PFS, progression-free survival; NRM, non-
relapse mortality; URD, unrelated donor; MRD, matched related donor;
CI, confidence interval.
*Cumulative incidence.CMV seropositivity, year of transplantation, and
busulfan dose were not risk factors.
In a multivariable Cox regressionmodel for OS us-
ing the same factors, there was no difference between
URD and MRD (HR 0.86, 95% CI 0.66-1.13;
P 5 .29). Prior HSCT (HR 1.51, 95% CI 1.10-2.07;
P 5 .01), high-risk disease (HR 1.49, 95% CI 1.11-
2.00; P 5 .008), and myeloid malignancy (HR 1.90,
95%CI 1.40-2.58; P\ .0001) were associated with in-
ferior OS (Figure 4A).Effect of Donor Type in Disease Subsets
PFS and relapse benefit for URD was observed in
both high- and low-risk diseases (Figure 5). For pa-
tients transplanted with high-risk disease, 2-year PFS
was 30% for URD, versus 16% for MRD (P 5 .027),
and 2-year cumulative incidence of relapse was 62%
in URD versus 75% in MRD (P 5 .03). For patients
transplanted with low-risk disease, 2 year PFS was
52% for URD, 42% for MRD (P 5 .03). The 2-year
cumulative incidence of relapse was 38% in URD
and 56% in MRD (P 5 .006). In multivariable CoxTable 2b. Results of Multivariable Regression Analysis* for
URD versus MRD
HR 95% CI P Value
Relapse 0.67 0.52 0.86 .002
NRM 1.27 0.64 2.52 .49
PFS 0.69 0.54 0.88 .002
OS 0.86 0.66 1.13 .29
HR indicates hazard ratio; CI, confidence interval; NRM, nonrelapse
mortality; PFS, progression-free survival; OS, overall survival.
*Adjusting for age, prior ablative transplant, risk status, donor-recipient
gender.
(F/M versus other), graft-versus-host disease (GVHD) prophylaxis (siro-
limus versus other), year of transplant, donor-recipient cytomegalovirus
(CMV) status (any positive versus neg/neg), conditioning regimen (Flu/
Bu2 versus Flu/Bu1).
Figure 3. Kaplan-Meier estimate of Survival after RIC HSCT. (A) PFS;
(B) OS.
Biol Blood Marrow Transplant 17:1196-1204, 2011 1201URD vs. MRD in RIC HSCTmodels stratified by disease risk, URD is associated
with improved PFS in both low-risk (HR. 0.67, 95%
CI 0.452-1.00, P 5 .05) and high-risk disease cohorts
(HR 0.69, 95% CI 0.52-0.95, P 5 .02).
There was a trend toward improved PFS for URD
in both myeloid and lymphoid malignancies: 2-year
PFS 34% versus 24% in myeloid (P 5 .09) and 45%
versus 35% in lymphoid (P 5 .06). There was no sta-
tistically significant difference in PFS outcomes for
any single disease diagnosis.
Additional Analyses
To assess whether the inclusion of HLA-C mis-
matches affected the results, we performed a subset
analysis on patients who were 8/8 HLA match (n 5
405). The 2-year cumulative incidence of disease re-
lapse was 52% in the 8/8 matched URD cohort, and
66% in the MRD (P 5 .008). PFS at 2 years was
40% for 8/8 matched URD and 29% for MRD (P 5
.01). These results suggest that the imbalance in
HLA-C mismatches in the URD cohort did not ac-
count for the benefit in relapse and PFS we observed.To assess the effect of CD341 dose, we performed
additional multivariable modeling including CD341
dose as a covariate. CD341 dose was not associated
with a difference in PFS or OS (P 5 .10 and .56, re-
spectively), and inclusion of CD341 dose in the model
did not change the hazard ratio showing benefit for
URD over MRD.
Because donor age and donor type were highly cor-
related (clustering analysis R-squared correlation 5
.81), we assessed the effect of donor age on PFS in
the MRD and URD cohorts separately. In a Cox re-
gression model, increasing donor age had no effect
on PFS in either the MRD or the URD cohorts (HR
1.01, P 5 .31 for MRD; HR 0.99, P 5 .26 for URD).
To investigate why the improvements in relapse
and PFS in the URD cohort did not translate to an
OS benefit, we performed additional analyses consid-
ering salvage therapies after relapse. Of the 244 pa-
tients who relapsed after RIC HSCT, 123/246 (50%)
in URD and 121/187 (65%) in MRD, 63 underwent
subsequent ‘‘salvage’’ allogeneic HSCT. There were
more patients in theMRD cohort who received salvage
HSCT: 31 (17%) in MRD versus 32 (13%) in URD,
P5 .34. In fact, 12/31 (39%) patients who relapsed af-
ter MRD actually received $2 salvage allo-HSCT,
compared to 7/32 (22%) in the URD group (P5 .13).
There were also more patients who received donor
leukocye infusions (DLI) for relapse after transplant
in the MRD versus URD: 20% versus 10% (P5 .006).
To assess whether subsequent HSCT might have
obscured our ability to observe a OS benefit, we per-
formed a subset analysis excluding patients (n 5 63)
who received salvage HSCT. When salvage HSCT
patients were excluded, the 2-year OS advantage for
URD over MRD increased from 6% (56% versus
50%) to 10% (57% versus 47%). Although this 10%
OS difference did not reach statistical significance
(P 5 .23), perhaps because of reduced sample size,
this trend is consistent with the improvement in
PFS. In a multivariable Cox model, there was also
a trend toward improved OS in favor of URD,
(HR 5 0.77 P 5 .08). These results suggest that sal-
vage HSCT after relapses may have, at least in part,
negated differences in OS.DISCUSSION
This study represents a large single-institution se-
ries of patients receiving a uniform Flu/Bu RIC
HSCT. We observed a significant improvement in
disease relapse and PFS for patients transplanted using
6/6 or 8/8 HLA matched URD compared with MRD
without increased GVHD, graft failure, or NRM.
We did not observe a difference in OS, but this could
reflect, in part, the fact that many patients, especially
in the MRD group, proceeded to a second or
Figure 4. Multivariable regression modeling showing hazard ratios and 95% confidence intervals. (A) OS; (B) PFS; (C) Relapse; (D) NRM.
Figure 5. PFS of URD and MRD cohorts, stratified by disease risk.
1202 Biol Blood Marrow Transplant 17:1196-1204, 2011V. T. Ho et al.subsequent allogeneic transplantation, and that pa-
tients may survive longer despite relapse because of
improved supportive and palliative therapies in recent
years.
Investigators from Seattle have reported their non-
myeloablative HSCT experience including 221 MRD
and 184 URD patients after 2 Gy TBI 6 fludarabine
conditioning [16]. They also did not observe any
increase inGVHDorNRM in theURD cohort. How-
ever, they did not detect any significant difference in
relapse based on related or unrelated donor type.
The discordance with our findings may reflect differ-
ences in the conditioning regimens, GVHD prophy-
laxis, and distribution of diseases. In the Seattle
series, all URD patients received Flu/TBI as condi-
tioning, whereas among MRD patients, 60% received
Flu/total body irridiation (TBI), and 40% received
low-dose TBI alone. More recently, the Seattle group
reported on 274 AML patients who received non-
myeloablative HSCT with 2 Gy TBI 6 fludarabine,
along with a calcineurin inhibitor and mycophenolatemofetil [17]. They found equivalent incidence of re-
lapse and survival for recipients of matched related
and unrelated donors.
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Group has also reported on the effect of donor type
on RIC HSCT outcomes in elderly patients with
AML [12]. In a retrospective cohort analysis of 368 pa-
tients, Schetelig and colleagues found no association
between donor type and AML relapse. However, in
subset analysis of patients with high-risk cytogenetics
and advanced disease, there was an improvement in
event-free survival (29% versus 6%, P 5 .04) for
URD. In this study, a majority of URD patients also
received ATG, compared to a minority in the MRD
cohort, which could have confounded relapse results.
Another publication by Hegenbart and colleagues
reported on the outcomes of low-dose TBI-based non-
myeloablative transplantation for AML across the
United States and European centers [15]. There was
again no significant difference in GVHD or TRM,
but a trend toward a lower relapse incidence at 2 years
for URD compared with MRD (33% versus 47%, P5
.12). Taken together, these results suggest that in RIC
and nonmyeloablative HSCT, matched URD are at
least comparable to MRD, and that URD might be
superior in certain disease subsets.
Aside from minor HLA antigen differences, URD
transplantation may be more likely to engender anti-
leukemic activity mediated by natural killer (NK) cells
on the basis of KIR mismatches, especially in patients
with myeloid malignancies [25]. As such, further stud-
ies to assess for potential effect of KIRmismatchesmay
be warranted. In our study, we are unable to assess the
impact of HLA-C mismatching because the numbers
of patients with this mismatch were small (n 5 28).
Our analysis is fortified by its large sample size
and the fact that both MRD and URD cohorts had
extended follow-up, and were well balanced in disease
characteristics, disease risk, prior HSCT, and GVHD
prophylaxis regimens. Importantly, all patients re-
ceived similar Flu/Bu conditioning without ATG
or ex vivo T cell depletion, thereby eliminating con-
ditioning regimen heterogeneity as a potential con-
founding factor. These considerations aside, our
study is subject to inherent limitations because of its
retrospective nature, and there may be uncontrolled
factors that could have biased results. For example, 1
potential confounding factor is the longer time needed
to identify unrelated donors compared to a donor in
the family. As a result, some patients with aggressive
malignancies could relapse before a volunteer donor
is found, potentially confounding results in favor of
URD. Conversely, there may also be selection bias in
favor of MRD because patients with less aggressive
malignancies are more likely to be offered transplanta-
tion if there is a family donor available.
It is also conceivable that sirolimus, with its poten-
tial antineoplastic properties, could have affected re-
lapse outcomes after RIC HSCT, at least in certain
disease subsets [26]. The fact that both the MRD andURD cohorts were identical with respect to percent-
age receiving sirolimus GVHD prophylaxis, and that
sirolimus was not a significant factor for PFS or relapse
in our multivariable models, appear to mitigate this
issue. Nonetheless, by minimizing differences in
GVHD and TRM between MRD and URD, use of si-
rolimus could have allowed the reduction in relapse in
the URD cohort to result in a more discernable im-
provement in PFS [27]. It is also possible that the
high relapse rates we observed, especially in MRD
patients, reflect the fact that by minimizing aGVHD,
sirolimus also blunted the GVL effect. In this context,
our findings of benefit for URD over MRD may only
be applicable to Flu/Bu RIC with tacrolimus/
sirolimus-based GVHD prophylaxis, and caution
should be exercised when extending these results to
HSCT employing other conditioning or GVHD pro-
phylaxis regimens.
An important consideration in the discussion of re-
lated versus unrelated donor choice in RIC HSCT is
the issue of donor age. Because RICHSCT is primarily
offered to older patients, siblings are likely to be older
than volunteer unrelated donors. Previous studies have
shown that increased donor age is associated with infe-
rior PBSCmobilization [28], delayed immune recovery
[29], greater risk ofGVHD, andworse survival [30,31].
Given these considerations, one may question the
desirability of older sibling donors when healthier,
younger matched unrelated donors are available. In
our analysis, we found that the median age of related
donors was indeed much older than that of unrelated
donors. The CD34 dose infused in the URD cohort
was also greater than that in MRD. However, neither
variable was independently associated with relapse or
PFS in multivariable analyses.
In summary, our results demonstrate that matched
URDRICHSCTwith fludarabine (Flu)/busulfan (Bu)
conditioning and primarily tacrolimus/sirolimus-
based GVHD prophylaxis is associated with an
improvement in disease relapse and PFS for URD,
possibly reflecting greater GVL activity, without ap-
parent increase in GVHD or NRM compared to
MRD. Further studies are warranted. If verified, these
findings could alter current clinical practice regarding
selection of donors for RIC transplantation.ACKNOWLEDGMENTS
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